Compare BTBD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTBD | SBFM |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 4.3M |
| IPO Year | 2019 | 2008 |
| Metric | BTBD | SBFM |
|---|---|---|
| Price | $1.96 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 28.9K | ★ 189.4K |
| Earning Date | 05-15-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,823,472.00 | ★ $36,305,891.00 |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 4.11 |
| 52 Week Low | $1.03 | $0.25 |
| 52 Week High | $2.48 | $3.05 |
| Indicator | BTBD | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 72.60 | 30.73 |
| Support Level | $1.10 | $0.27 |
| Resistance Level | $1.93 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 90.91 | 13.02 |
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.